NGS based RNA sequencing Market

Increased usage of next-generation sequencing technologies fuels market growth

The rising implementation of next-generation sequencing technologies is the main driver of the market CAGR for NGS-based RNA-sequencing. Rapid advances in next-generation sequencing techniques, as well as the creation of a human genome database, have enabled companies to provide rapid diagnostic services and the ability to diagnose mutations and disorders in human gene sequences by studying the entire human genome's structure, function, and organization.

Furthermore, when compared to the traditional Sanger sequencing technique, it significantly reduces the cost of performing sequential studies while also providing improved variant detection power and sensitivity by allowing the sequencing of millions of DNA fragments per run at the same time. The techniques offer great processing speed and throughput, allowing for the generation of a large number of sequences with numerous applications in both research and diagnostics. Researchers are fully researching and developing more prospectuses, which are likely to boost the performance of these procedures as a reliable solution and accelerate global market expansion over the forecast period.

The NGS-based RNA sequencing market is being driven by the growing field of precision medicine. Precision medicine enables doctors to create personalized treatment regimens and make treatment decisions based on a genetic understanding of the patient's ailment. Precision medicines are becoming increasingly popular for treating serious diseases such as cancer. NGS-based RNA sequencing aids in the identification of the underlying cause of disease and the prescription of precise precision medicine treatments.

For instance, in September 2021, the Swedish government invested $21.15 million (SEK 220 million) in the Swedish national infrastructure Genomic Medicine Sweden (GMS) to facilitate the continued integration of precision medicine into Swedish healthcare, ensuring that every person has access to more accurate tests and individualized care. Such expenditures are being made because of an increase in demand for precision medications. As demand for precision medicines grows, so will the demand for NGS-based RNA sequencing.

Moreover, The increasing pharmaceutical industry is likely to drive future growth in the NGS-based RNA-sequencing market. The pharmaceutical industry is the sector in which both government and commercial companies discover, develop, and manufacture pharmaceuticals and medicines. The pharmaceutical sector employs NGS-based RNA-sequencing to thoroughly analyze gene expression, identify prospective drug targets, assess treatment responses, and comprehend disease mechanisms, thereby aiding drug discovery and development through a better understanding of molecular processes.

For instance, in May 2021, according to reports published by IQVIA Inc., a US-based pharmaceutical company, the projected total expenditure on pharmaceuticals in the US is expected to range between $380 and $400 billion by 2025, up from $359 billion in 2020, reflecting a 0-3% compound annual growth rate. Thus driving the NGS-based RNA-sequencing Market revenue.

The Global NGS-based RNA-sequencing Market Industry is experiencing a surge in demand for personalized medicine, driven by advancements in genomics and biotechnology. Personalized medicine tailors treatment strategies based on individual genetic profiles, enhancing therapeutic efficacy. As healthcare systems increasingly adopt precision medicine approaches, RNA-sequencing technologies are pivotal in identifying biomarkers and understanding disease mechanisms. This trend is reflected in the projected market growth, with the Global NGS-based RNA-sequencing Market expected to reach 3.2 USD Billion in 2024 and potentially 22.0 USD Billion by 2035, indicating a robust CAGR of 19.14% from 2025 to 2035.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America is predicted to have the greatest revenue share during the projection period. The presence of well-established healthcare infrastructure, high healthcare spending, and an increasing prevalence of chronic diseases all contribute to market revenue growth in this region. This region also has a large concentration of major biopharmaceutical companies and sequencing service suppliers. The usage of personalized treatment methods and precision medicine is also fuelling regional market revenue growth.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: NGS-Based RNA-Sequencing Market Share By Region 2023 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe NGS-based RNA-sequencing Market accounts for the second-largest market share. The sector is driven by factors such as the proliferation of academic and research institutes, as well as an increase in demand for personalized therapy. Further, the German NGS-based RNA-sequencing Market held the largest market share, and the UK NGS-based RNA-sequencing Market was the fastest-growing market in the European region.

The Asia-Pacific NGS-based RNA-sequencing Market is expected to grow at the fastest CAGR from 2024 to 2032. The market is being pushed by an increase in genetic research programs, increased healthcare infrastructure expenditure, and growing public awareness of the benefits of personalized treatment. Moreover, China’s NGS-based RNA-sequencing Market held the largest market share, and the Indian NGS-based RNA-sequencing Market was the fastest-growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the NGS-based RNA-sequencing Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the NGS-based RNA-sequencing industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global NGS-based RNA-sequencing industry to benefit clients and increase the market sector. In recent years, the NGS-based RNA-sequencing industry has offered some of the most significant advantages to medicine. Major players in the NGS-based RNA-sequencing Market, including Illumina (the U.S.), Thermo Fischer Scientific (the U.S.), Oxford Nanopore Agilent Technologies, Inc. (the U.S.) and others, are attempting to increase market demand by investing in research and development operations.

Thermo Fisher Scientific Inc. is an American company that provides analytical equipment, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical, and biotechnology services. Thermo Fisher, headquartered in Waltham, Massachusetts, was created in 2006 when Thermo Electron and Fisher Scientific merged. In February 2024, BGI and Berry Genomics announced a collaboration to develop an AI-powered platform for analyzing RNA-seq data. This platform aims to improve the accuracy and efficiency of RNA-seq data analysis, leading to faster and more precise diagnosis and treatment methods.

QIAGEN N.V. is a German-based international company that develops sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company has around 35 offices throughout 25 countries. QIAGEN N.V., the QIAGEN group's global headquarters, is based in Venlo, Netherlands. The major operational headquarters are in Hilden, Germany. The European, American, Chinese, and Asian-Pacific regional headquarters are located in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. In June 2020, Qiagen launched the QIAcube Connect, a completely automated sample preparation system for NGS and other molecular biology applications.

The system is intended to deliver high-quality, reproducible outcomes with minimal human participation.